These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 19107404)
1. Enhancement of immunotherapeutic effects of HPV16E7 on cervical cancer by fusion with CTLA4 extracellular region. Zheng Y; Zhang Y; Ma Y; Wan J; Shi C; Huang L J Microbiol; 2008 Dec; 46(6):728-36. PubMed ID: 19107404 [TBL] [Abstract][Full Text] [Related]
2. Fusion protein vaccines targeting two tumor antigens generate synergistic anti-tumor effects. Cheng WF; Chang MC; Sun WZ; Jen YW; Liao CW; Chen YY; Chen CA PLoS One; 2013; 8(9):e71216. PubMed ID: 24058440 [TBL] [Abstract][Full Text] [Related]
3. Bivalent therapeutic vaccine against HPV16/18 genotypes consisting of a fusion protein between the extra domain A from human fibronectin and HPV16/18 E7 viral antigens. Arribillaga L; Echeverria I; Belsue V; Gomez T; Lozano T; Casares N; Villanueva L; Domingos-Pereira S; Romero PJ; Nardelli-Haefliger D; Hervás-Stubbs S; Sarobe P; Rodriguez MJ; Carrascosa JL; Zürcher T; Lasarte JJ J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581060 [TBL] [Abstract][Full Text] [Related]
4. Immunological responses and anti-tumor effects of HPV16/18 L1-L2-E7 multiepitope fusion construct along with curcumin and nanocurcumin in C57BL/6 mouse model. Kayyal M; Bolhassani A; Noormohammadi Z; Sadeghizadeh M Life Sci; 2021 Nov; 285():119945. PubMed ID: 34516991 [TBL] [Abstract][Full Text] [Related]
5. Induction of CD4-independent E7-specific CD8+ memory response by heat shock fusion protein. Liu H; Wu BH; Rowse GJ; Emtage PC Clin Vaccine Immunol; 2007 Aug; 14(8):1013-23. PubMed ID: 17596433 [TBL] [Abstract][Full Text] [Related]
6. A virosomal immunization strategy against cervical cancer and pre-malignant cervical disease. Bungener L; de Mare A; de Vries-Idema J; Sehr P; van der Zee A; Wilschut J; Daemen T Antivir Ther; 2006; 11(6):717-27. PubMed ID: 17310816 [TBL] [Abstract][Full Text] [Related]
7. Suppression of antitumour protective cytotoxic T lymphocyte responses to a human papillomavirus 16 E7 DNA vaccine by coinjection of interleukin-12 complementary DNA: involvement of nitric oxide in immune suppression. Sin JI Immunology; 2009 Sep; 128(1 Suppl):e707-17. PubMed ID: 19740332 [TBL] [Abstract][Full Text] [Related]
8. Immunological protection against HPV16 E7-expressing human esophageal cancer cell challenge by a novel HPV16-E6/E7 fusion protein based-vaccine in a Hu-PBL-SCID mouse model. Lu Y; Zhang Z; Liu Q; Liu B; Song X; Wang M; Zhao X; Zhao Q Biol Pharm Bull; 2007 Jan; 30(1):150-6. PubMed ID: 17202676 [TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of a human papillomavirus type 16 E7-expressing tumor by administration of fusion protein comprised of Mycobacterium bovis BCG Hsp65 and HPV16 E7. Chu NR; Wu HB; Wu TC; Boux LJ; Mizzen LA; Siegel MI Cell Stress Chaperones; 2000 Nov; 5(5):401-5. PubMed ID: 11189443 [TBL] [Abstract][Full Text] [Related]
10. [Expression of the human papillomavirus type 16L/E7 fusion protein in E. coli and observation of its immunogenicity in mice]. Tian HW; Ye ZM; Lu ZH; Jao R; Bian T; Zhao L; Ruan L Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Jun; 20(2):33-7. PubMed ID: 16816859 [TBL] [Abstract][Full Text] [Related]
11. HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity. Yin R; Zheng W; Hao F; Yang XC; Zhong BY; Li QJ J Dermatol Sci; 2009 Aug; 55(2):116-22. PubMed ID: 19500947 [TBL] [Abstract][Full Text] [Related]
12. A novel therapeutic vaccine composed of a rearranged human papillomavirus type 16 E6/E7 fusion protein and Fms-like tyrosine kinase-3 ligand induces CD8 Li J; Chen S; Ge J; Lu F; Ren S; Zhao Z; Pu X; Chen X; Sun J; Gu Y Vaccine; 2017 Nov; 35(47):6459-6467. PubMed ID: 29029939 [TBL] [Abstract][Full Text] [Related]
13. HPV16 E5 peptide vaccine in treatment of cervical cancer in vitro and in vivo. Liao SJ; Deng DR; Zeng D; Zhang L; Hu XJ; Zhang WN; Li L; Jiang XF; Wang CY; Zhou JF; Wang SX; Zhang HW; Ma D J Huazhong Univ Sci Technolog Med Sci; 2013 Oct; 33(5):735-742. PubMed ID: 24142729 [TBL] [Abstract][Full Text] [Related]
14. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors. Li YL; Qiu XH; Shen C; Liu JN; Zhang J Oncol Rep; 2010 Nov; 24(5):1323-9. PubMed ID: 20878127 [TBL] [Abstract][Full Text] [Related]
15. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7. Chu NR; Wu HB; Wu T; Boux LJ; Siegel MI; Mizzen LA Clin Exp Immunol; 2000 Aug; 121(2):216-25. PubMed ID: 10931134 [TBL] [Abstract][Full Text] [Related]
16. The efficacy of a DNA vaccine containing inserted and replicated regions of the E7 gene for treatment of HPV-16 induced tumors. Brinkman JA; Xu X; Kast WM Vaccine; 2007 Apr; 25(17):3437-44. PubMed ID: 17241713 [TBL] [Abstract][Full Text] [Related]
17. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth. Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735 [TBL] [Abstract][Full Text] [Related]
18. A Chlamydomonas-derived Human Papillomavirus 16 E7 vaccine induces specific tumor protection. Demurtas OC; Massa S; Ferrante P; Venuti A; Franconi R; Giuliano G PLoS One; 2013; 8(4):e61473. PubMed ID: 23626690 [TBL] [Abstract][Full Text] [Related]
19. A novel "priming-boosting" strategy for immune interventions in cervical cancer. Liao S; Zhang W; Hu X; Wang W; Deng D; Wang H; Wang C; Zhou J; Wang S; Zhang H; Ma D Mol Immunol; 2015 Apr; 64(2):295-305. PubMed ID: 25575128 [TBL] [Abstract][Full Text] [Related]
20. Rational design of DNA vaccines for the induction of human papillomavirus type 16 E6- and E7-specific cytotoxic T-cell responses. Oosterhuis K; Aleyd E; Vrijland K; Schumacher TN; Haanen JB Hum Gene Ther; 2012 Dec; 23(12):1301-12. PubMed ID: 22971245 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]